Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by garygpon Dec 01, 2021 4:54pm
116 Views
Post# 34187231

RE:RE:RE:Special Shareholders meeting

RE:RE:RE:Special Shareholders meeting The BOD has asked shareholders for "permission" to consolidate the shares if and when required, and allegedly for the betterment of all concerned. 

Should a consolidation take place, and it probably will, it could happen tomorrow, next week, next month, next year or never.

What Helllll posted is entirely true.  This is how corporations take control of a company and liquidate current shareholders into the stone age.  After this is done current shareholders have little if any voice in the direction the company is then taken and this is why some on this board have spoken out strenuously over the past many months.

In the not too distant future we will find out just how well our new partnership will treat us but I'm not holding my breath.  This for now is a real crapp shoot imo. 

What should really take is try and get the share price higher over the next 6 months then do a consolidation at higher prices, thus limiting the damage done by a ridiculous ratio of 60:1 and consider a more tolerable one of say 20:1.
<< Previous
Bullboard Posts
Next >>